Arginine methyltransferases critically regulate cellular homeostasis by modulating the functional outcome of their substrates. The protein arginine methyltransferase 5 (PRMT5) is an enzyme involved in growth and survival pathways promoting tumorigenesis. However, little is known about the biologic function of PRMT5 and its therapeutic potential in multiple myeloma (MM). In the present study, we identified and validated PRMT5 as a new therapeutic target in MM. PRMT5 is overexpressed in patient MM cells and associated with decreased progression-free survival and overall survival. Either genetic knockdown or pharmacological inhibition of PRMT5 with the inhibitor EPZ015666 significantly inhibited growth of both cell lines and patient MM cells. Furthermore, PRMT5 inhibition abrogated NF-κB signaling. Interestingly, mass spectrometry identified a tripartite motif-containing protein 21 TRIM21 as a new PRMT5-partner, and we delineated a TRIM21-dependent mechanism of NF-κB inhibition. Importantly, oral administration of EPZ015666 significantly decreased MM growth in a humanized murine model of MM. These data both demonstrate the oncogenic role and prognostic relevance of PRMT5 in MM pathogenesis, and provide the rationale for novel therapies targeting PRMT5 to improve patient outcome.
INTRODUCTION
Multiple myeloma (MM) is a lethal malignancy characterized by clonal proliferation of plasma cells in the bone marrow (BM). 1 Intrinsic genomic complexity drives a multistep progression from a pre-malignant condition (monoclonal gammopathy of undetermined significance) to overt disease. 2, 3 A deeper analyses of the genomic, epigenomic and proteomic landscape in MM is required to identify novel therapeutic targets. 3 An emerging field of investigation is the role of aberrant posttranslational modifications (PTMs) in cancer initiation and progression. [4] [5] [6] [7] So far, particular emphasis is on arginine methylation, a PTM catalyzed by protein methyltransferases (PRMTs), which affects key cellular processes via modulation of gene transcription and/or protein function. 8, 9 Among the others, PRMT5 is a major type II PRMT enzyme which catalyzes the symmetric transfer of up to two methyl groups to arginine residues. 10 Methylation by PRMT5 modulates the biological function of target proteins and is essential to maintain homeostasis in both normal and malignant cells. [11] [12] [13] Interestingly, it is frequently overexpressed in human cancer [14] [15] [16] [17] and its increased activity has been shown to support cell transformation. 15, 18 To date, several nuclear and cytoplasmic substrates of PRMT5 have been described: 19 for instance, p53 was recently identified as PRMT5 substrate and PRMT5-mediated arginine methylation in p53 impairs its DNA-binding and tumor-suppressor activity. 20 In this study, we investigate for the first time the role of PRMT5 in MM pathophysiology. Moreover, we provide the rational framework for its therapeutic targeting by a recently developed selective and orally bioavailable PRMT5 inhibitor (EPZ015666). 21 
MATERIALS AND METHODS
Methods and any associated references are available in the Supplementary Methods section.
RESULTS
PRMT5 overexpression has clinical impact on MM patient outcome.
The first aim of our study was to investigate whether PRMT5 can be a potential novel therapeutic target for MM patients. To this end, CD138+ immunopurified cells from a cohort of newly diagnosed MM patients (n = 320) or healthy donors (n = 16) were analyzed by RNA-seq. Interestingly, significant upregulation of PRMT5 was observed in patient MM (pMM) cells ( Figure 1a ). Moreover, analysis of PRMT5 expression in transplant eligible MM patients enrolled in the IFM/DFCI 2009 clinical study (NCT01191060) 22 showed that higher PRMT5 expression was associated with shorter overall survival (P = 0.018) and progression-free survival (P = 0.016) ( Figure 1b ). Additional analysis of PRMT5 expression in other independent MM patient data sets (GSE6477, GSE5900 and GSE2658) [23] [24] [25] showed that upregulation of PRMT5 was associated with disease progression (Supplementary Figure S1a-b). By qRT-PCR, we found upregulated PRMT5 in MM cell lines as compared with healthy donor plasma cells (Supplementary Figure S1c ). Moreover, both immunohistochemical staining of BM biopsies and western blotting (WB) of PRMT5 indicated its upregulation at protein level in pMM cells (Figure 1c and Supplementary Figure S1d ). This finding was also confirmed, by WB, in MM cell lines (n = 13) as compared with PBMCs (n = 3) (Supplementary Figure S1e) . Of note, a parallel increase of cellular symmetric arginine di-methylation (SDMA) substrates was also noted in the same samples (Supplementary Figure S1e ). Overall, these findings provide evidence that PRMT5 is overexpressed in MM patients and portends poor clinical outcome.
RNAi-or drug-mediated inhibition of PRMT5 decreases MM cell growth and survival in a p53-independent manner The functional significance of PRMT5 in MM cells was first addressed in RNAi-mediated loss-of-function experiments. Specifically, silencing of PRMT5 by siRNAs decreased proliferation in H929, KMS11, MM1S, U266, RPMI-8226 and AMO1 MM cells (Figure 2a and Supplementary Figure S2a ), along with induction of apoptotic markers (Supplementary Figure S2b) . Moreover, the anti-proliferative effect by PRMT5 downregulation was further confirmed by lentivirally transduced shRNAs targeting PRMT5 (shPRMT5 #1, #2 and #3) in both H929 (p53wt) and KMS11 (p53null) cells. As shown in Figure 2b , shPRMT5 #3 impaired proliferation of both MM cell lines, independent of the p53 mutational status. Importantly, decreased proliferation was associated with a decrease of SDMA levels (Supplementary Figure S2c ).
The effect of PRMT5 inhibition on p53 methylation was next explored in p53wt MM cells. As expected, PRMT5 silencing by siRNA reduced p53 methylation (Supplementary Figure S3a) , along with increased p53 transcriptional activity (Supplementary Figure S3b ). Despite this effect, either transient or lentiviral p53 silencing did not abrogate the anti-proliferative and pro-apoptotic activity induced by PRMT5 knockdown (Supplementary Figure  S3c-d) . These findings indicate a p53-independent anti-MM activity of PRMT5.
EPZ015666 is a specific inhibitor of PRMT5. 21 We next investigated its effect on a large panel of MM cell lines (n = 16). Proliferation of MM cell lines treated with increasing concentrations of EPZ015666 was inhibited in a dose-dependent fashion independent of their p53 mutational status ( Figure 2c ). Of note, EPZ015666 inhibited proliferation of dexamethasone (MM1R), bortezomib (ABZB) or carfilzomib (ACFZ)-refractory cells and IL-6-dependent INA-6 cells ( Figure 2c ). Anti-proliferative activity of EPZ015666 was associated with a parallel decrease of SDMA levels (Supplementary Figure S2d ). Importantly, EPZ015666 treatment significantly inhibited DNA synthesis and clonogenicity and induced apoptosis in H929 and KMS11 cells (Supplementary Figure S2e -h). In a parallel analysis, a slight increased proliferation was observed in KMS11 and H929 lentivirally transduced to overexpress PRMT5 (Supplementary Figure S2i ). Moreover, ectopic PRMT5 rescued anti-MM activity of EPZ015666 in KMS11 cells, indicating that drug activity is an on-target effect (Supplementary Figure S2l ). These findings demonstrate a potent anti-proliferative effect of PRMT5 inhibition in MM cells, and provide evidence supporting therapeutic targeting of PRMT5 in MM via the pharmacologic inhibitor EPZ015666.
EPZ015666 inhibits growth of CD138+ patient MM cells and overcomes the protective effect of the huBMM
The human bone marrow microenvironment (huBMM) exerts a protective role on MM cells. 26 Here we show by WB analysis that expression of both PRMT5 and SDMA in H929 and KMS11 is increased after culture with BM stromal cells-conditioned medium (Figure 3a and Supplementary Figure S4a ), implicating PRMT5 in huBMM-mediated pro-MM survival signaling. Importantly, EPZ015666 exerted its anti-proliferative effect in H929 and KMS11 even in the presence of BM stromal cells-conditioned medium (Figure 3b and Supplementary Figure S4b ).
Pro-survival signaling and oncogene-dependency could differ in
CD138+pMM cells compared to MM cell lines. We show that EPZ015666 also inhibited growth in pMM cells (n = 2) cultured on a BMSCs monolayer, and also induced apoptosis of pMM cells (n = 2) within BM mononuclear cell cultures ( Figure 3c ). Importantly, EPZ015666 did not affect the viability of health PBMCs, even though SDMA expression was decreased (Supplementary Figure S4c-d ).
EPZ015666 inhibits NF-κB signaling by triggering an IKKbeta (IKKβ) inhibitor-like gene signature Molecular perturbations induced by EPZ015666 were next investigated at the transcriptome level. Unsupervised hierarchical clustering segregated samples based on treatment identified a coherent transcriptome modulation induced by EPZ015666 (data not shown). Gene set enrichment analysis was performed to identify biological pathways affected by EPZ015666 in KMS11 MM cells.
Importantly, an open-ended enrichment analysis including the Hallmark gene sets collection available from Molecular Signature Database 27 revealed that the transcriptional signature of NF-κb-dependent genes (Hallmark_TNFA_Signaling_via_NF-kB) strongly correlated with genes downregulated by EPZ015666 (Normalized enrichment score = − 3.15, false discovery rate ⩽ 0.0001) (Supplementary Figure S5a and Supplementary Table  S1 ). Genes that were differentially expressed after EPZ015666 treatment were analyzed by Ingenuity pathway Analysis. In particular, Upstream Regulator Analysis identified NF-κB1 as a transcriptional regulator of the observed gene expression changes, and predicted its inactivation after EPZ015666 treatment (data not shown). The NF-κB pathway has a central role in the pathophysiology of MM. 28 Previous observations identified a NF-κB gene signature by integrating genes co-expressed in MM cell lines with those modulated after IKKβ inhibition. 29 Interestingly, a significant downregulation of the depicted NF-κB signature was found in EPZ015666-treated cells (Supplementary Figure S5b ). Downregulation was further confirmed by RT-PCR in 9 of 11 genes in the signature (NF-κBIA, RELB, TNFAIP3, NF-κBIE, MALT1, BIRC3, CD74, ILRG2 and NF-κB2) in KMS11 treated with EPZ015666 (Supplementary Figure S5c) . Moreover, consistent with a IKKβ inhibitor-like activity, IKKβ protein expression significantly decreased in KMS11, H929 and pMM cells exposed to EPZ015666 (Figure 4a ). Accordingly, WB revealed a concentration-dependent decrease of NF-κB p50 subunit within the nuclear fraction in KMS11 MM cells (Figure 4b ). Indeed, measurement of NF-κB DNA-binding activity in nuclear extracts from treated cells showed a decrease of DNA binding by complexes containing p65 and p50 subunits (Figure 4c ). Of note, inhibition of NF-κB by EPZ015666 was observed only in MM cells, and was not detected in healthy PBMCs (Supplementary Figure S5d ). These findings, including in silico inference and orthogonal validation, identify and confirm that inhibition of NF-κB pathway is a molecular consequence of PRMT5 inhibition.
Functional interaction of PRMT5 with the E3 ubiquitin ligase TRIM21 Based on above findings, our next aim was to delineate the functional mechanism of PRMT5 inhibition on NF-κB signaling. Indeed, this functional interaction likely accounts, at least in part, for the anti-MM activity of EPZ015666. Thus, we next identified PRMT5-interacting proteins in MM cells. Specifically, we analyzed proteins in immunocomplexes that co-precipitated with PRMT5 in PRMT5-overexpressing (KMS11-PRMT5) cells. PRMT5-associated proteins were submitted to mass spectrometry. As expected, a large number of novel or established partners were identified. Among these, the E3 ubiquitin ligase TRIM21 (also known as Ro52) was further studied, as it was a high affinity PRMT5-binding partner present only in PRMT5-associated complexes. The PRMT5-TRIM21 interaction was further confirmed by WB analysis of PRMT5-immunoprecipitated proteins (Figure 5a ). Moreover, arginine methylation of TRIM21 in lysates from KMS11 cells was decreased after treatment with EPZ015666 (Figure5b), indicating the functional significance of PRMT5/TRIM21 interaction. Of note, stable silencing of TRIM21 in MM cell lines significantly abrogated the anti-proliferative effect of EPZ015666 (Figure 5c ). Overall, these findings show that TRIM21 function is regulated by PRMT5induced arginine methylation, and provide the rationale to explore the role of TRIM21 in mediating the anti-proliferative activity of PRMT5 inhibition.
EPZ015666 triggers TRIM21-mediated autophagic proteolysis of IKKβ
Previous findings showed that TRIM21 monoubiquitinates IKKβ, 30 and that this modification triggers its degradation via selective autophagy. 31, 32 Specifically, proteins in the TRIM family may selectively induce degradation of targeted proteins due to sequence-specific recognition and formation of an autophagic complex, which shuttles the cargo protein into the autophagosome. 33 Here we hypothesized that the interaction of TRIM21 with PRMT5 blocks TRIM21-mediated degradation of IKKβ, allowing activation of NF-κB signaling. Indeed, consistent with our hypothesis, increased IKKβ monoubiquitination ( Figure 6a ) and formation of IKKβ-TRIM21-pBECLIN1 autophagic complexes ( Figure 6b ) was detected after treatment of MM cells with EPZ015666. Moreover, fluorescence microscopy analysis confirmed colocalization of IKKβ in the autophagosome after treatment with EPZ015666 (Figure 6c and Supplementary Figure S6a ). Conversely, exposure of MM cells to 3-methyladenine, an inhibitor of autophagosome formation, rescued EPZ015666induced growth inhibition in KMS11 and H929 (Figure 6d and Supplementary Figure S6b) . At protein level, 3-methyladenine prevented the degradation of endogenous IKKβ (Supplementary Figure S6c ). Taken together, these data indicate that PRMT5mediated TRIM21 methylation has a key regulatory function of NF-κB signaling in MM cells mediated via inhibition of autophagic proteolysis of IKKβ (Figure 6e ). Indeed, direct inhibition of the PRMT5/TRIM21 axis mediates anti-MM activity of EPZ015666.
Oral EPZ015666 treatment inhibits tumor growth of MM xenografts in NOD SCID mice
In vivo anti-MM activity of EPZ015666 was next investigated in NOD severe combined immunodeficiency mice bearing subcutaneous GFP + -KMS11 xenografts. Mice received twice-daily oral treatment with 150 mg/kg EPZ015666 for 21 days. Importantly, this treatment resulted in a significant inhibition of tumor growth ( Figures 7a and b and Supplementary Figure S7a ). Kaplan-Meier curves showed a significantly prolonged survival in the EPZ015666-treated group (log-rank analysis P = 0.0001), with a median survival of 30 days in control mice versus 66 days in the EPZ015666-treated cohort (Figure 7c ). WB analysis of tumors retrieved from EPZ015666-treated mice confirmed in vivo target inhibition by EPZ015666, assessed by decreased SDMA substrates (Supplementary Figure S7b) . These data demonstrate that PRMT5 inhibition by EPZ015666 inhibits in vivo growth of MM xenografts and prolongs survival without adverse toxicity profile, providing the preclinical rationale for its clinical evaluation in MM.
DISCUSSION
In the present study, we identified PRMT5 as a prognostic marker and promising therapeutic target in MM. Our data suggest that overexpression of PRMT5 has a significant role of in MM pathogenesis, since it progressively increases during MM progression, as well as correlates with clinical outcome. We show MM dependence on PRMT5, as genetic knockdown via RNAiapproaches inhibits growth and induces apoptosis of both MM cell lines and patient MM cells. These effects are observed in both p53wt and p53null MM cell lines, suggesting that the oncogenic role of PRMT5 does not rely on p53 status in MM.
To explore the potential clinical translation of PRMT5 inhibition, we examined the anti-MM activity of a recently described PRMT5 inhibitor EPZ015666. Importantly, proliferation of both p53wt and p53null MM cells was inhibited by this agent. Previous reports have shown that p53 is a direct target of PRMT5, which alters its target gene specificity by arginine methylation. 20 Consistent with these findings, we show that p53 transcriptional activity was enhanced in H929 p53wt cells by either siPRMT5 or EPZ015666 treatment. However, our data show that activation of p53 transcriptional activity is not essential for growth inhibition triggered by downregulation of PRMT5, since genetic knockdown of p53 by shRNAs in AMO1 (p53wt) did not decrease sensitivity to EPZ015666. Among p53 mutated cells, only SKMM1 and OPM--2 MM cells are insensitive to EPZ015666; these cell lines have a p53 mutation on codon 175, which represents a hotspot gain-offunction mutation possibly involved in resistance to EPZ015666. This mutation is rarely observed in MM patients, 34, 35 and therefore has not been further studied here. Altogether, we found that EPZ015666 treatment decreased DNA synthesis, clonogenicity and induced apoptosis in MM cells, without impacting normal donor PBMCs, suggesting a favorable therapeutic index. The interplay between MM cells and their huBMM drives disease progression through promotion of pro-survival and drug resistance pathways. 26 Notably, we here observed an increase of PRMT5 expression after culture of MM cells in BMSC-conditioned media. These data suggests involvement of PRMT5 in huBMMmediated MM cell protective signaling, and a potential direct effect of huBMM stimuli on PRMT5 transcription, which is currently the object of ongoing studies. Importantly, EPZ015666 retains its anti-MM activity against either MM cell lines or patient MM cells cultured with BMSCs-conditioned media or with adhesion to BMSCs, indicating that EPZ015666 can overcome drug resistance owing to the interplay of tumor cells with their huBMM. 26 To date, multiple oncogenic pathways have been described which are directly affected by PRMT5. 19 By transcriptome analysis, we here identified a new interplay between PRMT5 with the NF-κB survival pathway which could account, at least part, for MM dependence on PRMT5. Specifically, we found downregulated NF-κB transcriptional signatures in MM cells exposed to EPZ015666. Additional validation of this outcome was carried out by qRT-PCR, analysis of NF-κB DNA-binding activity, and immunoblotting. Of note, our findings overlapped with those obtained by Annunziata et al. 29 after MM cell exposure to an IKKβ inhibitor, and our protein analysis showed markedly decreased IKKβ expression in MM cell lines and pMM cells after treatment with EPZ015666. Hence, we hypothesized a mechanism involving IKKβ degradation. To address this point, we searched by mass spectrometry for direct interactors linking PRMT5 to IKKβ; and importantly, this analysis identified the E3 ubiquitin (Ub)-ligase TRIM21. This interaction was further validated by detection of TRIM21 protein in PRMT5 immunocomplexes. TRIM family proteins are known to regulate different cellular processes, and their altered activity can sustain carcinogenesis. 36 Specifically, a large body of evidence has characterized their role in selective autophagy: by acting as autophagy receptors, they allow the formation of the autophagy platform or 'TRIMosome', promoting the selective degradation of tagged-cargo proteins. 32, 33 As for other TRIM proteins, TRIM21 acts as autophagy receptor. 37 Importantly, it inhibits NF-κB signaling by driving direct IKKβ monoubiquitination and its subsequent degradation through an autophagy-mediated mechanism. 30, 31 In our studies, EPZ015666 decreased TRIM21 SDMA and increased monoubiquitination of IKKβ, consistent with PRMT5-mediated regulation of TRIM21 functions. Indeed, arginine methylation, along with other PTMs, has been shown to modulate autophagy receptor activity. 38, 39 Importantly, we here show that EPZ015666 promotes formation of IKKβ-TRIM21-pBECLIN1 autophagic complexes, as assessed by fluorescence microscopy and WB. Of note, both the RNAi-mediated silencing of TRIM21 and the inhibition of autophagosome formation by 3 − methyladenine abrogates the anti-MM activity of EPZ015666. Together, these findings indicate that the anti-MM activity of EPZ015666 is due to inhibition of canonical NF-κB signaling. Mechanistically, they indicate that PRMT5/NF-κB interplay takes place via TRIM21, a newly identified interactor of PRMT5, which governs selective autophagy-mediated turn-over of IKKβ.
Finally, we demonstrated a potent in vivo growth-inhibitory activity of EPZ015666 against human MM xenografts in NOD severe combined immunodeficiency mice, without attendant toxicities to normal tissues. Indeed, oral administration of EPZ015666 resulted in a complete inhibition of tumor growth, associated with target inhibition and its sequelae in tumors harvested from treated mice. Further studies using in vivo models recapitulating the huBMM 40, 41 will better define the effects of PRMT5 inhibition in the BM milieu: indeed, our prior studies have shown that NF-κB regulates adhesion molecule expression on MM cells and BM cells, as well as modulates transcription of MM growth and survival factors such as interleukin-6. 42 Altogether, our findings define the role of PRMT5 in MM pathogenesis, and provide the preclinical rationale for clinical trials targeting PRMT5 with EPZ015666 to improve patient outcome in MM.
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